Br J Urol 1998 Dec;82(6):928
Department of Dermatology, Soroka Medical Center, Berr-Sheva, Israel.
Am J Trop Med Hyg 2001 Nov;65(5):466-70
Center for Health Studies, Universidad del Valle de Guatemala, Guatemala.
A double-blind, randomized trial was undertaken in Guatemala to determine the therapeutic efficacy of an ointment for the treatment of cutaneous leishmaniasis that contained 15% paromomycin and 12% methylbenzethonium chloride and that was applied twice a day for 20 days. The treatment group included 35 patients, and the placebo group included 33 patients. The initial clinical response rate (13 weeks after completing the treatment) was 91. Read More
Hautarzt 1994 Nov;45(11):783-6
Hautklinik, Universitätskrankenhauses Eppendorf, Hamburg.
A 19-year-old male patient with chronic cutaneous leishmania is was treated topically with paromomycin sulphate (15%) and methylbenzethonium chloride (12%) in petrolatum album. After application twice daily for two periods of 32 and 44 days the lesions were completely healed. Previous treatment for 9 months with ketoconazole (400 mg/day) together with the topical application of thiabendazole (2. Read More
Br Med J (Clin Res Ed) 1985 Sep;291(6497):704-5
Trans R Soc Trop Med Hyg 1994 Jan-Feb;88(1):92-4
Institute of Tropical Hygiene and Public Health, University of Heidelberg, Germany.
Fifty-two patients with American cutaneous leishmaniasis (ACL) from the Pacific coast of Ecuador were treated topically with an ointment containing 15% paramomycin (PR) and 12% methylbenzethonium chloride (MBCL) in vaselinum album (white soft paraffin; white petrolatum). After 20 applications (over 10 or 20 d) all lesions showed complete epithelialization within the first 100 d. Five patients developed new lesions during the one year observation period; 2 of these were probably reinfections. Read More